{
    "abstract": "Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) are remarkably effective inducing deep molecular remission in most patients. However, they are less effective to eradicate the leukemic stem cells (LSC), resulting in disease persistence. Therefore, there is great need to develop novel therapeutic strategies to specifically target the LSC. In an experimental mouse CML model system, the leukotriene pathway, and specifically, the expression ALOX5, encoding 5-lipoxygenase (5-LO), has been reported as a critical regulator of the LSC. Based on these results, the 5-LO inhibitor zileuton has been introduced in clinical trials as a therapeutic option to target the LSC although its effect on primary human CML LSC has not been studied. We have here by using multiplex single cell PCR analyzed the expression of the mediators of the leukotriene pathway in bone marrow (BM) BCR-ABL+CD34+CD38\u2212 cells at diagnosis, and found low or undetectable expression of ALOX5. In line with this, zileuton did not exert significant overall growth inhibition in the long-term culture-initiating cell (LTC-IC) and colony (CFU-C) assays of BM CD34+CD38\u2212 cells from 7 CML patients. The majority of the single leukemic BCR-ABL+CD34+CD38\u2212 cells expressed cysteinyl leukotriene receptors CYSLT1 and CYSLT2. However, montelukast, an inhibitor of CYSLT1, also failed to significantly suppress CFU-C and LTC-IC growth. These findings indicate that targeting ALOX5 or CYSLT1 signaling with leukotriene antagonists, introduced into the clinical practice primarily as prophylaxis and treatment for asthma, may not be a promising pharmacological strategy to eradicate persisting LSC in CML patients.",
    "bib_entries": {
        "bib1": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Savona"
                },
                {
                    "first": "Moshe",
                    "initial": "M.",
                    "last": "Talpaz"
                }
            ],
            "doi": "10.1038/nrc2368",
            "firstpage": "341",
            "issn": "1474175X",
            "lastpage": "350",
            "pmid": "18385684",
            "pub_year": 2008,
            "title": "Getting to the stem of chronic myeloid leukaemia",
            "volume": "8"
        },
        "bib10": {
            "authors": [
                {
                    "first": "Mikael",
                    "initial": "M.",
                    "last": "Sj\u00f6linder"
                },
                {
                    "first": "Leif",
                    "initial": "L.",
                    "last": "Stenke"
                },
                {
                    "first": "Barbro",
                    "initial": "B.",
                    "last": "N\u00e4sman-Glaser"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Widell"
                },
                {
                    "first": "Johanne",
                    "initial": "J.",
                    "last": "Doucet"
                },
                {
                    "first": "Per Johan",
                    "initial": "P.J.",
                    "last": "Jakobsson"
                },
                {
                    "first": "Jan \u00c5ke",
                    "initial": "J.A.",
                    "last": "Lindgren"
                }
            ],
            "firstpage": "1456",
            "issn": "00064971",
            "lastpage": "1464",
            "pmid": "10666225",
            "pub_year": 2000,
            "title": "Aberrant expression of active leukotriene C4 synthase in CD16+ neutrophils from patients with chronic myeloid leukemia",
            "volume": "95"
        },
        "bib11": null,
        "bib12": {
            "authors": [
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Baccarani"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "Deininger"
                },
                {
                    "first": "Gianantonio",
                    "initial": "G.",
                    "last": "Rosti"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Hochhaus"
                },
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Soverini"
                },
                {
                    "first": "Jane F.",
                    "initial": "J.F.",
                    "last": "Apperley"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Cervantes"
                },
                {
                    "first": "Richard E.",
                    "initial": "R.E.",
                    "last": "Clark"
                },
                {
                    "first": "Jorge E.",
                    "initial": "J.E.",
                    "last": "Cortes"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Guilhot"
                },
                {
                    "first": "Henrik",
                    "initial": "H.",
                    "last": "Hjorth-Hansen"
                },
                {
                    "first": "Timothy P.",
                    "initial": "T.P.",
                    "last": "Hughes"
                },
                {
                    "first": "Hagop M.",
                    "initial": "H.M.",
                    "last": "Kantarjian"
                },
                {
                    "first": "Dong Wook",
                    "initial": "D.W.",
                    "last": "Kim"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Larson"
                },
                {
                    "first": "Jeffrey H.",
                    "initial": "J.H.",
                    "last": "Lipton"
                },
                {
                    "first": "Fran\u00e7ois Xavier",
                    "initial": "F.X.",
                    "last": "Mahon"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Martinelli"
                },
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Mayer"
                },
                {
                    "first": "Martin C.",
                    "initial": "M.C.",
                    "last": "M\u00fcller"
                },
                {
                    "first": "Dietger",
                    "initial": "D.",
                    "last": "Niederwieser"
                },
                {
                    "first": "Fabrizio",
                    "initial": "F.",
                    "last": "Pane"
                },
                {
                    "first": "Jerald P.",
                    "initial": "J.P.",
                    "last": "Radich"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Rousselot"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Saglio"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Sau\u00dfele"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Schiffer"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Silver"
                },
                {
                    "first": "Bengt",
                    "initial": "B.",
                    "last": "Simonsson"
                },
                {
                    "first": "Juan Luis",
                    "initial": "J.L.",
                    "last": "Steegmann"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Goldman"
                },
                {
                    "first": "R\u00fcdiger",
                    "initial": "R.",
                    "last": "Hehlmann"
                }
            ],
            "doi": "10.1182/blood-2013-05-501569",
            "firstpage": "872",
            "issn": "00064971",
            "lastpage": "884",
            "pmid": "23803709",
            "pub_year": 2013,
            "title": "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013",
            "volume": "122"
        },
        "bib13": {
            "authors": [
                {
                    "first": "D. E.",
                    "initial": "D.E.",
                    "last": "Hogge"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Lansdorp"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Reid"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Gerhard"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Eaves"
                }
            ],
            "firstpage": "3765",
            "issn": "00064971",
            "lastpage": "3773",
            "pmid": "8916940",
            "pub_year": 1996,
            "title": "Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor",
            "volume": "88"
        },
        "bib14": {
            "authors": [
                {
                    "first": "W. M.",
                    "initial": "W.M.",
                    "last": "Wong"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Dolinska"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Sigvardsson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ekblom"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Qian"
                }
            ],
            "doi": "10.1038/leu.2015.300",
            "firstpage": "1399",
            "issn": "08876924",
            "lastpage": "1402",
            "pmid": "26500141",
            "pub_year": 2016,
            "title": "A novel Lin-CD34+CD38-integrin \u03b12-bipotential megakaryocyte-erythrocyte progenitor population in the human bone marrow",
            "volume": "30"
        },
        "bib15": {
            "authors": [
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Qian"
                },
                {
                    "first": "Aurora",
                    "initial": "A.",
                    "last": "Badaloni"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Chiara"
                },
                {
                    "first": "Jenny",
                    "initial": "J.",
                    "last": "Stjernberg"
                },
                {
                    "first": "Naresh",
                    "initial": "N.",
                    "last": "Polisetti"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Nihlberg"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Giacomo Consalez"
                },
                {
                    "first": "Mikael",
                    "initial": "M.",
                    "last": "Sigvardsson"
                }
            ],
            "doi": "10.1128/MCB.01287-12",
            "firstpage": "661",
            "issn": "02707306",
            "lastpage": "677",
            "pmid": "23184664",
            "pub_year": 2013,
            "title": "Molecular characterization of prospectively isolated multipotent mesenchymal progenitors provides new insight into the cellular identity of mesenchymal stem cells in mouse bone marrow",
            "volume": "33"
        },
        "bib17": null,
        "bib18": {
            "authors": [
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Jiang"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Zhao"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Smith"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Gasparetto"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Turhan"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Eaves"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Eaves"
                }
            ],
            "doi": "10.1038/sj.leu.2404609",
            "firstpage": "926",
            "issn": "08876924",
            "lastpage": "935",
            "pmid": "17330101",
            "pub_year": 2007,
            "title": "Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies",
            "volume": "21"
        },
        "bib19": {
            "authors": [
                {
                    "first": "Lorraine",
                    "initial": "L.",
                    "last": "Burke"
                },
                {
                    "first": "Clare T.",
                    "initial": "C.T.",
                    "last": "Butler"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Murphy"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Moran"
                },
                {
                    "first": "William M.",
                    "initial": "W.M.",
                    "last": "Gallagher"
                },
                {
                    "first": "Jacintha",
                    "initial": "J.",
                    "last": "O'Sullivan"
                },
                {
                    "first": "Breand\u00e1n N.",
                    "initial": "B.N.",
                    "last": "Kennedy"
                }
            ],
            "doi": "10.3389/fcell.2016.00103",
            "issn": "2296634X",
            "pub_year": 2016,
            "title": "Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer",
            "volume": "4"
        },
        "bib2": {
            "authors": [
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Rongzhen",
                    "initial": "R.",
                    "last": "Xu"
                }
            ],
            "doi": "10.1007/s13238-015-0143-7",
            "firstpage": "403",
            "issn": "1674800X",
            "lastpage": "412",
            "pmid": "25749979",
            "pub_year": 2015,
            "title": "Leukemia stem cells: the root of chronic myeloid leukemia",
            "volume": "6"
        },
        "bib20": {
            "authors": [
                {
                    "first": "Meifang",
                    "initial": "M.",
                    "last": "Xiao"
                },
                {
                    "first": "Hongmei",
                    "initial": "H.",
                    "last": "Ai"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Li"
                },
                {
                    "first": "Pasupati",
                    "initial": "P.",
                    "last": "Rajoria"
                },
                {
                    "first": "Prakash",
                    "initial": "P.",
                    "last": "Shahu"
                },
                {
                    "first": "Xiansong",
                    "initial": "X.",
                    "last": "Li"
                }
            ],
            "doi": "10.1016/j.bbrc.2016.03.018",
            "firstpage": "610",
            "issn": "0006291X",
            "lastpage": "616",
            "pmid": "26966074",
            "pub_year": 2016,
            "title": "Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function",
            "volume": "472"
        },
        "bib21": {
            "authors": [
                {
                    "first": "Adriana C.",
                    "initial": "A.C.",
                    "last": "Drost"
                },
                {
                    "first": "Gabriele",
                    "initial": "G.",
                    "last": "Seitz"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Boehmler"
                },
                {
                    "first": "Mirjam",
                    "initial": "M.",
                    "last": "Funk"
                },
                {
                    "first": "Karoline Pia",
                    "initial": "K.P.",
                    "last": "Norz"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Zipfel"
                },
                {
                    "first": "Xingkui",
                    "initial": "X.",
                    "last": "Xue"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Kanz"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "M\u00f6hle"
                }
            ],
            "doi": "10.3109/10428194.2011.625578",
            "firstpage": "665",
            "issn": "10428194",
            "lastpage": "673",
            "pmid": "21936770",
            "pub_year": 2012,
            "title": "The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia",
            "volume": "53"
        },
        "bib22": {
            "authors": [
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Bautz"
                },
                {
                    "first": "Claudio",
                    "initial": "C.",
                    "last": "Denzlinger"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Kanz"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "M\u00f6hle"
                }
            ],
            "doi": "10.1182/blood.V97.11.3433",
            "firstpage": "3433",
            "issn": "00064971",
            "lastpage": "3440",
            "pmid": "11369634",
            "pub_year": 2001,
            "title": "Chemotaxis and transendothelial migration of CD34+ hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1",
            "volume": "97"
        },
        "bib23": {
            "authors": [
                {
                    "first": "Andreas M.",
                    "initial": "A.M.",
                    "last": "Boehmler"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Drost"
                },
                {
                    "first": "Lena",
                    "initial": "L.",
                    "last": "Jaggy"
                },
                {
                    "first": "Gabriele",
                    "initial": "G.",
                    "last": "Seitz"
                },
                {
                    "first": "Tina",
                    "initial": "T.",
                    "last": "Wiesner"
                },
                {
                    "first": "Claudio",
                    "initial": "C.",
                    "last": "Denzlinger"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Kanz"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "M\u00f6hle"
                }
            ],
            "doi": "10.4049/jimmunol.0801525",
            "firstpage": "6789",
            "issn": "00221767",
            "lastpage": "6798",
            "pmid": "19454674",
            "pub_year": 2009,
            "title": "The CysLT1 ligand leukotriene D4 supports \u03b1 4\u03b21- and \u03b15\u03b21- mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells",
            "volume": "182"
        },
        "bib24": {
            "authors": [
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Zarini"
                },
                {
                    "first": "Miguel A.",
                    "initial": "M.A.",
                    "last": "Gij\u00f3n"
                },
                {
                    "first": "Aaron E.",
                    "initial": "A.E.",
                    "last": "Ransome"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Murphy"
                },
                {
                    "first": "Angelo",
                    "initial": "A.",
                    "last": "Sala"
                }
            ],
            "doi": "10.1073/pnas.0903851106",
            "firstpage": "8296",
            "issn": "00278424",
            "lastpage": "8301",
            "pmid": "19416808",
            "pub_year": 2009,
            "title": "Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation",
            "volume": "106"
        },
        "bib3": {
            "authors": [
                {
                    "first": "Ravi",
                    "initial": "R.",
                    "last": "Bhatia"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Holtz"
                },
                {
                    "first": "Ning",
                    "initial": "N.",
                    "last": "Niu"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Gray"
                },
                {
                    "first": "David S.",
                    "initial": "D.S.",
                    "last": "Snyder"
                },
                {
                    "first": "Charles L.",
                    "initial": "C.L.",
                    "last": "Sawyers"
                },
                {
                    "first": "Daniel A.",
                    "initial": "D.A.",
                    "last": "Arber"
                },
                {
                    "first": "Marilyn L.",
                    "initial": "M.L.",
                    "last": "Slovak"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Forman"
                }
            ],
            "firstpage": "4701",
            "issn": "00064971",
            "lastpage": "4707",
            "pmid": "12576334",
            "pub_year": 2003,
            "title": "Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment",
            "volume": "101"
        },
        "bib4": {
            "authors": [
                {
                    "first": "Joanna M.",
                    "initial": "J.M.",
                    "last": "Poczobutt"
                },
                {
                    "first": "Teresa T.",
                    "initial": "T.T.",
                    "last": "Nguyen"
                },
                {
                    "first": "Dwight",
                    "initial": "D.",
                    "last": "Hanson"
                },
                {
                    "first": "Howard",
                    "initial": "H.",
                    "last": "Li"
                },
                {
                    "first": "Trisha R.",
                    "initial": "T.R.",
                    "last": "Sippel"
                },
                {
                    "first": "Mary C.M.",
                    "initial": "M.C.M.",
                    "last": "Weiser-Evans"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Gijon"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Murphy"
                },
                {
                    "first": "Raphael A.",
                    "initial": "R.A.",
                    "last": "Nemenoff"
                }
            ],
            "doi": "10.4049/jimmunol.1501648",
            "firstpage": "891",
            "issn": "00221767",
            "lastpage": "901",
            "pmid": "26663781",
            "pub_year": 2016,
            "title": "Deletion of 5-lipoxygenase in the tumor microenvironment promotes lung cancer progression and metastasis through regulating t cell recruitment",
            "volume": "196"
        },
        "bib5": {
            "authors": [
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Peters-Golden"
                },
                {
                    "first": "William R.",
                    "initial": "W.R.",
                    "last": "Henderson"
                }
            ],
            "doi": "10.1056/NEJMra071371",
            "firstpage": "1798",
            "issn": "00284793",
            "lastpage": "1854",
            "pmid": "17978293",
            "pub_year": 2007,
            "title": "Mechanisms of disease: Leukotrienes",
            "volume": "357"
        },
        "bib6": {
            "authors": [
                {
                    "first": "Yaoyu",
                    "initial": "Y.",
                    "last": "Chen"
                },
                {
                    "first": "Yiguo",
                    "initial": "Y.",
                    "last": "Hu"
                },
                {
                    "first": "Haojian",
                    "initial": "H.",
                    "last": "Zhang"
                },
                {
                    "first": "Cong",
                    "initial": "C.",
                    "last": "Peng"
                },
                {
                    "first": "Shaoguang",
                    "initial": "S.",
                    "last": "Li"
                }
            ],
            "doi": "10.1038/ng.389",
            "firstpage": "783",
            "issn": "10614036",
            "lastpage": "792",
            "pmid": "19503090",
            "pub_year": 2009,
            "title": "Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia",
            "volume": "41"
        },
        "bib7": {
            "authors": [
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "O'hare"
                },
                {
                    "first": "Matthew S.",
                    "initial": "M.S.",
                    "last": "Zabriskie"
                },
                {
                    "first": "Anna M.",
                    "initial": "A.M.",
                    "last": "Eiring"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "Deininger"
                }
            ],
            "doi": "10.1038/nrc3317",
            "firstpage": "513",
            "issn": "1474175X",
            "lastpage": "526",
            "pmid": "22825216",
            "pub_year": 2012,
            "title": "Pushing the limits of targeted therapy in chronic myeloid leukaemia",
            "volume": "12"
        },
        "bib8": {
            "authors": [
                {
                    "first": "Claire M.",
                    "initial": "C.M.",
                    "last": "Lucas"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Harris"
                },
                {
                    "first": "Athina",
                    "initial": "A.",
                    "last": "Giannoudis"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "McDonald"
                },
                {
                    "first": "Richard E.",
                    "initial": "R.E.",
                    "last": "Clark"
                }
            ],
            "doi": "10.3324/haematol.2013.101972",
            "firstpage": "1710",
            "issn": "03906078",
            "lastpage": "1715",
            "pmid": "25193960",
            "pub_year": 2014,
            "title": "Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia",
            "volume": "99"
        },
        "bib9": {
            "authors": [
                {
                    "first": "Cecilia",
                    "initial": "C.",
                    "last": "Roos"
                },
                {
                    "first": "Leif",
                    "initial": "L.",
                    "last": "Stenke"
                },
                {
                    "first": "Lotta",
                    "initial": "L.",
                    "last": "Ohm"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Widell"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Kumlin"
                },
                {
                    "first": "Jan \u00c5ke",
                    "initial": "J.A.",
                    "last": "Lindgren"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Tornhamre"
                }
            ],
            "doi": "10.1111/j.1365-2141.2008.07283.x",
            "firstpage": "992",
            "issn": "00071048",
            "lastpage": "995",
            "pmid": "18573108",
            "pub_year": 2008,
            "title": "Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia",
            "volume": "142"
        }
    },
    "body_text": [
        {
            "endOffset": 20629,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "BM aspirates collected from healthy adult volunteers and newly diagnosed patients with chronic phase CML (n = 10, Table S1) were used in accordance with approved protocols (LU-195-00, LU-826-2004, 2012/4:10 and 2013/3:1).",
            "startOffset": 20408,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 18602,
            "parents": [],
            "secId": "sec1",
            "sentence": "During LT biosynthesis from arachidonic acid, LTA4, an unstable intermediate product, is converted by LTA4 hydrolase (LTA4H) to LTB4 or by LTC4 synthase (LTC4S) to cysteinyl-containing LTC4, which is further metabolized to cysteinyl LTD4 and LTE4.",
            "startOffset": 18355,
            "title": "Introduction"
        },
        {
            "endOffset": 17917,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 17916,
                    "startOffset": 17913
                }
            },
            "secId": "sec1",
            "sentence": "Treatment with zileuton, an inhibitor of 5-LO, specifically inhibited the development of leukemia but did not inhibit the non-leukemic stem cells in this mouse model [6].",
            "startOffset": 17747,
            "title": "Introduction"
        },
        {
            "endOffset": 22736,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Imatinib and/or leukotriene antagonists or DMSO in the corresponding final concentration as in the inhibitors, were added at the initiation of the cultures, and the cultures were maintained at 37 \u00b0C and 5% CO2 for 6 weeks with weekly half-medium change.",
            "startOffset": 22483,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 16792,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 16562,
                    "startOffset": 16557
                },
                "bib2": {
                    "endOffset": 16562,
                    "startOffset": 16557
                }
            },
            "secId": "sec1",
            "sentence": "The leukemic stem cells (LSC) in chronic phase CML reside in a phenotypically similar stem and progenitor cell population (CD34+CD38\u2212) as normal bone marrow (BM) stem and progenitor cells [1,2] and differentiate predominantly into an expanding population of granulocytes, thrombocytes and their precursors, whereas in the terminal phase, blast crisis, immature lymphoid or myeloid progenitors accumulate as leukemic blasts.",
            "startOffset": 16369,
            "title": "Introduction"
        },
        {
            "endOffset": 17323,
            "parents": [],
            "secId": "sec1",
            "sentence": "Therefore, there is a great need to identify additional therapeutic strategies to specifically target LSC in CML.",
            "startOffset": 17210,
            "title": "Introduction"
        },
        {
            "endOffset": 16368,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 16367,
                    "startOffset": 16364
                }
            },
            "secId": "sec1",
            "sentence": "Chronic myeloid leukemia (CML) is characterized by the expression of the BCR-ABL fusion protein, a constitutively active tyrosine kinase that promotes growth of leukemic stem and progenitor cells by multiple signaling pathways involved in cell survival, proliferation and differentiation [1].",
            "startOffset": 16076,
            "title": "Introduction"
        },
        {
            "endOffset": 29651,
            "parents": [],
            "refoffsets": {
                "bib20": {
                    "endOffset": 29650,
                    "startOffset": 29646
                }
            },
            "secId": "sec4",
            "sentence": "In addition, the other LTB4 receptor BLT2 was found to be upregulated by BCR-ABL in primary CML blast crisis CD34+ progenitors, and inhibition of this receptor suppressed proliferation and induced apoptosis of the leukemic cells [20].",
            "startOffset": 29417,
            "title": "Discussion"
        },
        {
            "endOffset": 21378,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Imatinib and leukotriene antagonists were provided by Cayman Chemical Company (Ann Arbor, MI, USA).",
            "startOffset": 21279,
            "title": "Reagents"
        },
        {
            "endOffset": 25381,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The expression of LTA4H was overall high with median frequencies of 95.6% and 79.6% in the BCR-ABL+ and BCR-ABL- cells, respectively (Fig. 2B).",
            "startOffset": 25238,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 33025,
            "parents": [],
            "secId": "sec4",
            "sentence": "However, the expression and functional role of several other mediators of the LT pathway in human primitive hematopoietic stem and progenitor cells and their leukemic counterparts in CML remains elusive and should be assessed in further studies.",
            "startOffset": 32780,
            "title": "Discussion"
        },
        {
            "endOffset": 32454,
            "parents": [],
            "refoffsets": {
                "bib11": {
                    "endOffset": 32158,
                    "startOffset": 32154
                }
            },
            "secId": "sec4",
            "sentence": "In contrast to the reported inhibition of the growth of CML blast crisis cell lines by montelukast in a short term liquid culture assay [11], we did not find significant overall growth suppression of BM CD34+CD38\u2212 or CD34+ stem and progenitor cells of CML patients by montelukast in LTC-IC or CFU-C assays, suggesting that pharmacological inhibition of CYSLTR1 may not either be a promising therapeutic strategy for eradicating CML LSC.",
            "startOffset": 32018,
            "title": "Discussion"
        },
        {
            "endOffset": 24368,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Statistical differences were evaluated by Wilcoxon matched-pairs signed rank test.",
            "startOffset": 24286,
            "title": "Statistics"
        },
        {
            "endOffset": 20324,
            "parents": [],
            "secId": "sec1",
            "sentence": "These data suggest that targeting ALOX5 or CYSLT1 signaling with leukotriene signaling antagonists may not be a promising pharmacological strategy to eradicate CML LSC in patients in the clinic.",
            "startOffset": 20130,
            "title": "Introduction"
        },
        {
            "endOffset": 21268,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "The dead cells were excluded by propidium iodide (PI; Invitrogen) staining.",
            "startOffset": 21193,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 28405,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.4",
            "sentence": "In order to determine whether the LT inhibitors could specifically target the LSC in the LTC-IC cultures, we analyzed cells from these cultures by FISH for the BCR-ABL fusion gene.",
            "startOffset": 28225,
            "title": "Residual BCR-ABL+ cells were detected in single colonies from LTC-IC cultures"
        },
        {
            "endOffset": 19069,
            "parents": [],
            "refoffsets": {
                "bib11": {
                    "endOffset": 19068,
                    "startOffset": 19064
                }
            },
            "secId": "sec1",
            "sentence": "Recently, the expression of the CYSLT receptors in CML cell lines was reported [11], and montelukast, an inhibitor of CYSLT1, was found to suppress in vitro growth of CML blast crisis cell lines [11].",
            "startOffset": 18869,
            "title": "Introduction"
        },
        {
            "endOffset": 26787,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Similarly, no significant additive inhibition could be detected when the LT inhibitors were combined with imatinib (Fig. 3A,C).",
            "startOffset": 26660,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 32779,
            "parents": [],
            "secId": "sec4",
            "sentence": "Consequently, inhibiting 5-LO or CYSLTR1 by zileuton and montelukast may not be a promising option to eradicate CML LSC.",
            "startOffset": 32659,
            "title": "Discussion"
        },
        {
            "endOffset": 22482,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.4",
            "sentence": "The cells were seeded at 3, 10, 30 and 100 cells/well or 1, 3, 10 and 30 cells/well, 10\u201318 replicates except for 30 or 100 cells/well where a small total cell number in some cases restricted the number of replicates.",
            "startOffset": 22266,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 21475,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Stock solutions were prepared with DMSO (imatinib 10 mM, montelukast 50 mM and zileuton 100 mM).",
            "startOffset": 21379,
            "title": "Reagents"
        },
        {
            "endOffset": 24488,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "See supplemental materials for additional methods.",
            "startOffset": 24438,
            "title": "Statistics"
        },
        {
            "endOffset": 19682,
            "parents": [],
            "secId": "sec1",
            "sentence": "To assess the expression and function of LT signaling molecules in leukemic CD34+CD38\u2212 BM cells we have here employed multiplex single cell PCR and in vitro stem and progenitor cell assays using the LT inhibitors zileuton and montelukast, and cells from newly diagnosed CML patients.",
            "startOffset": 19399,
            "title": "Introduction"
        },
        {
            "endOffset": 23498,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Cell lysates were reverse transcribed using multiple pairs of gene-specific reverse primers and 50U MMLV-RT per reaction in the buffer provided by the supplier (200 U/ml, Life technologies).",
            "startOffset": 23308,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 23886,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Aliquots of second-round PCR products were subjected to gel electrophoresis and visualized by GelRed\u2122 staining (Invitrogen) on 1.5\u20133% agarose gel.",
            "startOffset": 23740,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 16969,
            "parents": [],
            "secId": "sec1",
            "sentence": "Tyrosine kinase inhibitors (TKI) including imatinib, targeting the BCR-ABL oncoprotein, have been remarkably effective in inducing deep molecular remission in most CML patients.",
            "startOffset": 16792,
            "title": "Introduction"
        },
        {
            "endOffset": 27111,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "However, in a BM sample (CML8) from a patient who progressed to blast crisis soon after diagnosis (Table S1), zileuton in combination with imatinib seemed to further suppress LTC-IC activity of the CD34+CD38\u2212 cells with the LTC-IC frequency reduced from 0.031 in zileuton alone to 0.018 in zileuton plus imatinib (Fig. 3A).",
            "startOffset": 26788,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 26386,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Imatinib induced a reduction of LTC-IC frequencies in CD34+CD38\u2212 cells from 6 out of 7 tested CML patient samples, representing a significant overall growth inhibition (median of 0.12, p = 0.03) (Fig. 3A, C).",
            "startOffset": 26178,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 21862,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The colony-forming units in culture (CFU-Cs) were counted at day 14.",
            "startOffset": 21794,
            "title": "Colony assays"
        },
        {
            "endOffset": 17746,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 17669,
                    "startOffset": 17666
                }
            },
            "secId": "sec1",
            "sentence": "In an experimental mouse CML model, the gene encoding 5-LO, ALOX5 was overexpressed in stem cells transfected with BCR-ABL [6], and loss of ALOX5 in the BCR-ABL+ LSC impaired the development of leukemia.",
            "startOffset": 17543,
            "title": "Introduction"
        },
        {
            "endOffset": 21793,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The purified CD34+CD38\u2212 or CD34+ cells were cultured at a density of 150 cells/dish (for CD34+ cells) or 50 cells/dish (for CD34+CD38\u2212 cells) in Methocult H4435 (Stem Cell Technologies) in duplicate.",
            "startOffset": 21594,
            "title": "Colony assays"
        },
        {
            "endOffset": 29860,
            "parents": [],
            "refoffsets": {
                "bib21": {
                    "endOffset": 29859,
                    "startOffset": 29855
                }
            },
            "secId": "sec4",
            "sentence": "High expression of CYSLTR1 was reported in chronic lymphocytic leukemia, and in vitro inhibition of it induced apoptosis of the leukemic cells, suggesting this receptor as a potential therapeutic target [21].",
            "startOffset": 29652,
            "title": "Discussion"
        },
        {
            "endOffset": 23307,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "The CD34+CD38\u2212 CML cells were deposited directly at 1 cell/well in 4 \u03bcL of lysis buffer (dNTPs, DTT, 10% NP40, RNase inhibitor) per well in 96-well plates (Thermo Scientific, #AB-0800).",
            "startOffset": 23122,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 30226,
            "parents": [],
            "secId": "sec4",
            "sentence": "Based on these reports suggesting a role for 5LO/ALOX5 and/or cysteinyl LT signaling in solid cancers and in leukemia, we have here focused on the expression of the target molecules of these two respective inhibitors zileuton and montelukast in primary BCR-ABL+ CD34+CD38\u2212 LSC from CML patient at diagnosis and their in vitro functional response to these inhibitors.",
            "startOffset": 29860,
            "title": "Discussion"
        },
        {
            "endOffset": 21192,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "The gates were set according to fluorescence-minus-one controls.",
            "startOffset": 21128,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 30372,
            "parents": [],
            "secId": "sec4",
            "sentence": "We show by single cell PCR assays that CYSLTR1 receptor is expressed in most leukemic and residual normal CD34+CD38\u2212 cells in BM of CML patients.",
            "startOffset": 30227,
            "title": "Discussion"
        },
        {
            "endOffset": 17448,
            "parents": [],
            "refoffsets": {
                "bib4": {
                    "endOffset": 17447,
                    "startOffset": 17442
                },
                "bib5": {
                    "endOffset": 17447,
                    "startOffset": 17442
                }
            },
            "secId": "sec1",
            "sentence": "Leukotrienes (LT) are biologically active lipid mediators involved in inflammatory processes and in malignant diseases [4,5].",
            "startOffset": 17323,
            "title": "Introduction"
        },
        {
            "endOffset": 20129,
            "parents": [],
            "secId": "sec1",
            "sentence": "Although the majority of the leukemic BCR-ABL+CD34+CD38\u2212 cells expressed CYSLT1 and CYSLT2 receptors, montelukast failed to significantly inhibit growth of CML BM CD34+CD38\u2212 cells.",
            "startOffset": 19949,
            "title": "Introduction"
        },
        {
            "endOffset": 24273,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "The primer sequences are listed in Table S2.",
            "startOffset": 24229,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 32018,
            "parents": [],
            "secId": "sec4",
            "sentence": "Our data suggest that targeting the ALOX5 gene product, 5-LO using zileuton to treat CML may not be as promising as expected from previously reported mouse studies.",
            "startOffset": 31854,
            "title": "Discussion"
        },
        {
            "endOffset": 22852,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Thereafter 140 \u03bcL of the medium was carefully removed and the wells were overlaid with 150 \u03bcL Methocult H4435/well.",
            "startOffset": 22737,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 31669,
            "parents": [],
            "secId": "sec4",
            "sentence": "Imatinib also significantly inhibited CFU-C growth of the leukemic BM progenitors.",
            "startOffset": 31587,
            "title": "Discussion"
        },
        {
            "endOffset": 27740,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.3",
            "sentence": "CFU-C assays were performed on CD34+ cells from 5 CML patients (Fig. 3E).",
            "startOffset": 27667,
            "title": "No overall significant inhibition of CFU-C from CML CD34+ cells by zileuton or montelukast"
        },
        {
            "endOffset": 22265,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib13": {
                    "endOffset": 22264,
                    "startOffset": 22260
                }
            },
            "secId": "sec2.4",
            "sentence": "The CD34+CD38\u2212 cells were sorted directly and plated in 200 \u03bcL Myelocult H5100 (Stem Cell Technologies), 10\u22126 M hydrocortisone (Sigma) in Collagen I coated or plain 96-well microplates (BD Biosciences) on irradiated (8000 cGy) murine stromal cell line M2-10B4 (10000 cells/well), engineered to express human cytokines, IL-3 and G-CSF [13].",
            "startOffset": 21926,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 28145,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.3",
            "sentence": "There was no significant inhibition in the colony growth by montelukast or zileuton.",
            "startOffset": 28061,
            "title": "No overall significant inhibition of CFU-C from CML CD34+ cells by zileuton or montelukast"
        },
        {
            "endOffset": 23010,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.4",
            "sentence": "The wells were scored as positive or negative after 14 days, and the frequencies of LTC-IC were calculated using the L-Calc software (StemCell Technologies).",
            "startOffset": 22853,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 31853,
            "parents": [],
            "secId": "sec4",
            "sentence": "In contrast, zileuton, did not induce any significant overall inhibition in the LTC-IC activity of CD34+CD38\u2212 cells or the CFU-C activity of CD34+ cells of the CML patient BM samples.",
            "startOffset": 31670,
            "title": "Discussion"
        },
        {
            "endOffset": 18868,
            "parents": [],
            "refoffsets": {
                "bib10": {
                    "endOffset": 18716,
                    "startOffset": 18709
                },
                "bib5": {
                    "endOffset": 18867,
                    "startOffset": 18864
                },
                "bib9": {
                    "endOffset": 18716,
                    "startOffset": 18709
                }
            },
            "secId": "sec1",
            "sentence": "The expression and activity of LTC4S has been shown to be increased in myeloid cells in patients with CML [9,10]. While LTB4 binds to receptors BLT1 and BLT2, the cysteinyl LT act on target cells mainly through the G-protein coupled receptors CYSLT1 and CYSLT2 [5].",
            "startOffset": 18603,
            "title": "Introduction"
        },
        {
            "endOffset": 24438,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "The two-sided p-value was considered to be significant when p < 0.05.",
            "startOffset": 24369,
            "title": "Statistics"
        },
        {
            "endOffset": 26177,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib17": {
                    "endOffset": 26176,
                    "startOffset": 26172
                }
            },
            "secId": "sec3.2",
            "sentence": "The median frequencies of LTC-IC in BM CD34+CD38\u2212 cells from CML patients and normal BM donors were 0.38 and 0.40, respectively, in agreement with a previous report [17].",
            "startOffset": 26007,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 23739,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "One microliter aliquots of first-round PCRs were further amplified using fully nested gene-specific primers.",
            "startOffset": 23631,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 33317,
            "parents": [],
            "secId": "sec5",
            "sentence": "M.E., L.S., S.M., U.O.S. have participated as investigators in several international clinical CML studies sponsored by pharmaceutical companies (Novartis, BMS, Pfizer and Ariad), generating remuneration to these individuals or to their respective institutions/departments.",
            "startOffset": 33045,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 25237,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The median frequency of residual nonleukemic BCR-ABL- cells expressing ALOX5 was similarly low (16.0%).",
            "startOffset": 25134,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 29167,
            "parents": [],
            "refoffsets": {
                "bib19": {
                    "endOffset": 29166,
                    "startOffset": 29162
                }
            },
            "secId": "sec4",
            "sentence": "In line with this, studies using in vivo murine colon cancer xenograft models have demonstrated notable potential of both zileuton and montelukast as anti-cancer agents, suggesting that inhibiting LT signaling may be a promising additional pharmacological strategy to target these tumors [19].",
            "startOffset": 28874,
            "title": "Discussion"
        },
        {
            "endOffset": 19399,
            "parents": [],
            "secId": "sec1",
            "sentence": "So far, the effects of montelukast and zileuton on the primary CD34+CD38\u2212 stem and progenitor cells from patients with CML have not been reported, even though zileuton, combined with TKI has already been introduced into clinical trials in CML (clinicaltrials.com, NCT02047149, NCT01130688) with as yet no available efficacy data.",
            "startOffset": 19070,
            "title": "Introduction"
        },
        {
            "endOffset": 21925,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib13": {
                    "endOffset": 21924,
                    "startOffset": 21917
                },
                "bib14": {
                    "endOffset": 21924,
                    "startOffset": 21917
                }
            },
            "secId": "sec2.4",
            "sentence": "LTC-IC assay was performed as described [13,14].",
            "startOffset": 21877,
            "title": "LTC-IC assay"
        },
        {
            "endOffset": 19948,
            "parents": [],
            "secId": "sec1",
            "sentence": "We found a low frequency of ALOX5-expressing CD34+CD38\u2212 cells in the CML patient samples, and no significant overall growth suppression of BM CD34+CD38\u2212 cells from CML patients by zileuton in the long-term culture-initiating cell (LTC-IC) and colony (CFU-C) assays.",
            "startOffset": 19683,
            "title": "Introduction"
        },
        {
            "endOffset": 17542,
            "parents": [],
            "secId": "sec1",
            "sentence": "The first step in LT biosynthesis is conversion of arachidonic acid by 5-lipoxygenase (5-LO).",
            "startOffset": 17449,
            "title": "Introduction"
        },
        {
            "endOffset": 23630,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "The first-round PCR with 35 cycles was performed by addition of 40 \u03bcl PCR buffer and 1.25 U Taq polymerase (TaKaRa kit, Clonetech).",
            "startOffset": 23499,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 28060,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Inhibition of CFU-C growth by imatinib was similar at 1 \u03bcM and 5 \u03bcM (Fig. S1).",
            "startOffset": 27982,
            "title": "No overall significant inhibition of CFU-C from CML CD34+ cells by zileuton or montelukast"
        },
        {
            "endOffset": 31291,
            "parents": [],
            "refoffsets": {
                "bib24": {
                    "endOffset": 31290,
                    "startOffset": 31286
                }
            },
            "secId": "sec4",
            "sentence": "However, the expression of downstream LTA4H in most leukemic and nonleukemic cells may indicate transcellular biosynthesis of LT downstream of 5-LO in the LSC, as reported in other cell types [24].",
            "startOffset": 31094,
            "title": "Discussion"
        },
        {
            "endOffset": 29251,
            "parents": [],
            "secId": "sec4",
            "sentence": "The role of LT signaling in human normal hematopoiesis and leukemia remains elusive.",
            "startOffset": 29167,
            "title": "Discussion"
        },
        {
            "endOffset": 25614,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The cysteinyl LT receptors CYSLTR1 and CYSLTR2 were also expressed in most BCR-ABL+ LSC (median frequency of 64.5% and 57,3%, respectively) and BCR-ABL- CD34+CD38\u2212 cells (median frequency of 71.7% and 81.7%, respectively) (Fig. 2B).",
            "startOffset": 25382,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 27262,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Cytopenias are known off-target effects of imatinib, and inhibition of LTC-IC activity by imatinib was seen in some healthy donor BM CD34+CD38\u2212 cells.",
            "startOffset": 27112,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 18066,
            "parents": [],
            "refoffsets": {
                "bib7": {
                    "endOffset": 18065,
                    "startOffset": 18062
                }
            },
            "secId": "sec1",
            "sentence": "Based on these results, zileuton was proposed to be an option to eradicate the human LSC and to offer potential to improve the treatment of CML [7].",
            "startOffset": 17918,
            "title": "Introduction"
        },
        {
            "endOffset": 24848,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "To specifically analyze the expression of LT signaling molecules in LSC, we determined the co-expression of BCR-ABL with LT pathway mediators ALOX5, CYSLTR1, CYSLTR2 and LTA4H mRNA in single BM CD34+CD38\u2212 cells from 8 CML patients (Table S1) by using nested RT-PCR (Fig. 1).",
            "startOffset": 24574,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 18355,
            "parents": [],
            "secId": "sec1",
            "sentence": "Its expression and function in the more primitive leukemic BCR-ABL+ CD34+CD38\u2212 cells of CML patients has not been explored.",
            "startOffset": 18232,
            "title": "Introduction"
        },
        {
            "endOffset": 23121,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib15": {
                    "endOffset": 23120,
                    "startOffset": 23116
                }
            },
            "secId": "sec2.5",
            "sentence": "Single-cell RT-PCR analysis was performed as previously described [15].",
            "startOffset": 23050,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 24041,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "The expression of BCR/ABL and the leukotriene pathway genes (CYSLTR1, CYSLTR2, ALOX5, and LTA4H) were analyzed simultaneously with HPRT, a reference gene.",
            "startOffset": 23887,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 21127,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "The CD34+ or CD34+CD38\u2212 cells were further sorted by FACSAriaIII Cell Sorter (BD Biosciences) after staining with monoclonal antibodies (BD Biosciences, San Jose, CA, USA), anti-CD34-FITC or APC (8G12) and anti-CD38-PECY7 or PE (HB7).",
            "startOffset": 20893,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 24228,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "The wells were defined as positive for containing one cell if they were positive for HPRT gene product, or for two of other genes in the GelRed\u2122 stained agarose gel if negative for HPRT.",
            "startOffset": 24042,
            "title": "Multiplex single-cell RT-PCR analysis"
        },
        {
            "endOffset": 20786,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Mononuclear cells were isolated by Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS, Oslo, Norway).",
            "startOffset": 20689,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 33393,
            "parents": [],
            "secId": "sec5",
            "sentence": "Other authors declare no competing financial interest regarding this study.",
            "startOffset": 33318,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 28616,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.4",
            "sentence": "We could detect residual BCR-ABL+ cells after all treatments (Fig. 4), showing that even when total LTC-IC frequencies were reduced by imatinib (Patients CML3, 7, and 9, Fig. 3), LSCs were not fully eradicated.",
            "startOffset": 28406,
            "title": "Residual BCR-ABL+ cells were detected in single colonies from LTC-IC cultures"
        },
        {
            "endOffset": 18231,
            "parents": [],
            "refoffsets": {
                "bib8": {
                    "endOffset": 18230,
                    "startOffset": 18227
                }
            },
            "secId": "sec1",
            "sentence": "However, low levels of ALOX5 transcript were found at diagnosis in CD34+ progenitors of patients with chronic phase CML as compared to normal CD34+ progenitors [8].",
            "startOffset": 18067,
            "title": "Introduction"
        },
        {
            "endOffset": 20892,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.1",
            "sentence": "The CD34+ cells were enriched by using CD34 MicroBead Kit (Miltenyi Biotech, Bergisch Gladbach, Germany).",
            "startOffset": 20787,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        },
        {
            "endOffset": 26006,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "To test the functional response of the primitive leukemic stem and progenitor cells to the LT inhibitors zileuton or montelukast alone and in combination with imatinib, we performed limiting dilution LTC-IC assay of BM CD34+CD38\u2212 cells from 7 CML patients and 5 healthy donors (Fig. 3).",
            "startOffset": 25720,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 24942,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The frequencies of the BCR-ABL+ cells were 38%\u201370% of the CD34+CD38\u2212 cells (Figs. 1C and 2A).",
            "startOffset": 24849,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 27574,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Although some inhibition by zileuton and montelukast, comparable to that observed in few CML samples, was seen in the LTC-IC assays of few normal BM samples, there was no significant overall decrease in LTC-IC frequencies in the normal BM in cultures with imatinib, LT inhibitors or the combination (Fig. 3B,D).",
            "startOffset": 27263,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 29416,
            "parents": [],
            "refoffsets": {
                "bib8": {
                    "endOffset": 29415,
                    "startOffset": 29412
                }
            },
            "secId": "sec4",
            "sentence": "The receptor for LTB4, BLT1 is expressed in CD34+ cells in CML at diagnosis and its expression appeared to be correlated with the clinical response to imatinib [8].",
            "startOffset": 29252,
            "title": "Discussion"
        },
        {
            "endOffset": 25133,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "Notably, ALOX5 was undetectable in one BM sample and was expressed only in a small fraction of leukemic BCR-ABL+CD34+CD38\u2212 cells in most BM samples with a median frequency of 10.6% (Fig. 2).",
            "startOffset": 24943,
            "title": "Expression of LT signaling molecules in single CML CD34+CD38\u2212BCR-ABL+ cells"
        },
        {
            "endOffset": 31586,
            "parents": [],
            "secId": "sec4",
            "sentence": "In the in vitro functional stem and progenitor cell assays of primary CD34+CD38\u2212 cells of CML patients, imatinib significantly inhibited the overall LTC-IC activity in leukemic, but not in normal donor BM samples, supporting a specific inhibitory effect on BCR-ABL+ LSC in these culture systems.",
            "startOffset": 31291,
            "title": "Discussion"
        },
        {
            "endOffset": 32658,
            "parents": [],
            "secId": "sec4",
            "sentence": "In summary, our findings indicate that the LT signaling pathway via ALOX5 or CYSLTR1 may be less important for survival of primary human CML LSCs than that of mouse BCR-ABL+ cells or CML blast cell lines.",
            "startOffset": 32454,
            "title": "Discussion"
        },
        {
            "endOffset": 31093,
            "parents": [],
            "secId": "sec4",
            "sentence": "By single cell PCR analysis we detected a very low overall frequency of ALOX5 expression in the primitive BCR-ABL+ CD34+CD38\u2212 LSC and BCR-ABL-CD34+CD38\u2212 nonleukemic cells of CML patients, suggesting distinct regulation and functional importance of 5-LO/ALOX5 in primitive human CML LSC and in the mouse BCR-ABL+LSC.",
            "startOffset": 30778,
            "title": "Discussion"
        },
        {
            "endOffset": 27981,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib18": {
                    "endOffset": 27980,
                    "startOffset": 27976
                }
            },
            "secId": "sec3.3",
            "sentence": "Not surprisingly, total CFU-Cs were dramatically suppressed by imatinib in all 9 assays of 6 patient samples (p = 0.03), in agreement with the reported more efficient suppression by imatinib of less primitive leukemic progenitor cells [18].",
            "startOffset": 27741,
            "title": "No overall significant inhibition of CFU-C from CML CD34+ cells by zileuton or montelukast"
        },
        {
            "endOffset": 30502,
            "parents": [],
            "secId": "sec4",
            "sentence": "We also find the expression of the CYSLTR2 in most of these cells, with a partially overlapping expression with CYSLTR1 receptor.",
            "startOffset": 30373,
            "title": "Discussion"
        },
        {
            "endOffset": 21578,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "The final concentrations used in cultures were imatinib 1 or 5 \u03bcM, and zileuton and montelukast 20 \u03bcM.",
            "startOffset": 21476,
            "title": "Reagents"
        },
        {
            "endOffset": 26659,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "In contrast to imatinib, neither zileuton nor montelukast were able to induce significant overall inhibition of LTC-IC growth of the 7 tested CML BM samples (Fig. 3A), although some reductions were observed in CML5 by 38.2% and in CML8 by 53% compared to the DMSO control.",
            "startOffset": 26387,
            "title": "Growth response of CML CD34+CD38\u2212BCR-ABL+ cells to imatinib and LT signaling inhibitors in LTC-IC assay"
        },
        {
            "endOffset": 28873,
            "parents": [],
            "secId": "sec4",
            "sentence": "Signaling pathways mediated by leukotrienes have been identified as important regulators of acute and chronic inflammation, but are also involved in the pathogenesis in several types of cancers, including colon, lung, prostate and breast cancers.",
            "startOffset": 28627,
            "title": "Discussion"
        },
        {
            "endOffset": 17209,
            "parents": [],
            "refoffsets": {
                "bib3": {
                    "endOffset": 17208,
                    "startOffset": 17205
                }
            },
            "secId": "sec1",
            "sentence": "However, TKI are less effective in eradicating the LSC, resulting in disease persistence, most often necessitating lifelong pharmacological therapy and carrying a risk for development of drug resistance and progression to blast crisis [3].",
            "startOffset": 16970,
            "title": "Introduction"
        },
        {
            "endOffset": 30778,
            "parents": [],
            "refoffsets": {
                "bib22": {
                    "endOffset": 30715,
                    "startOffset": 30708
                },
                "bib23": {
                    "endOffset": 30715,
                    "startOffset": 30708
                }
            },
            "secId": "sec4",
            "sentence": "CYSLTR1 mRNA has previously been shown to be expressed in normal hematopoietic CD34+ progenitors, and signaling via CYSLTR1 modulated adhesion, proliferation and transmigration of the progenitors in vitro [22,23], while the role of CYSLTR2 in hematopoiesis is so far unclear.",
            "startOffset": 30503,
            "title": "Discussion"
        },
        {
            "endOffset": 20688,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib12": {
                    "endOffset": 20687,
                    "startOffset": 20683
                }
            },
            "secId": "sec2.1",
            "sentence": "The WHO criteria for chronic phase CML were employed [12].",
            "startOffset": 20630,
            "title": "Human sample collection and CD34+CD38\u2212 cell sorting by FACS"
        }
    ],
    "docId": "S0006291X1731183X",
    "metadata": {
        "asjc": [
            "1303",
            "1304",
            "1307",
            "1312"
        ],
        "authors": [
            {
                "email": null,
                "first": "Monika",
                "initial": "M.",
                "last": "Dolinska"
            },
            {
                "email": null,
                "first": "Alexandre",
                "initial": "A.",
                "last": "Piccini"
            },
            {
                "email": null,
                "first": "Wan Man",
                "initial": "W.M.",
                "last": "Wong"
            },
            {
                "email": null,
                "first": "Eleni",
                "initial": "E.",
                "last": "Gelali"
            },
            {
                "email": null,
                "first": "Anne Sofie",
                "initial": "A.S.",
                "last": "Johansson"
            },
            {
                "email": null,
                "first": "Johannis",
                "initial": "J.",
                "last": "Klang"
            },
            {
                "email": null,
                "first": "Pingnan",
                "initial": "P.",
                "last": "Xiao"
            },
            {
                "email": null,
                "first": "Elham",
                "initial": "E.",
                "last": "Yektaei-Karin"
            },
            {
                "email": null,
                "first": "Ulla Olsson",
                "initial": "U.O.",
                "last": "Str\u00f6mberg"
            },
            {
                "email": null,
                "first": "Satu",
                "initial": "S.",
                "last": "Mustjoki"
            },
            {
                "email": null,
                "first": "Leif",
                "initial": "L.",
                "last": "Stenke"
            },
            {
                "email": null,
                "first": "Marja",
                "initial": "M.",
                "last": "Ekblom"
            },
            {
                "email": "hong.qian@ki.se",
                "first": "Hong",
                "initial": "H.",
                "last": "Qian"
            }
        ],
        "doi": "10.1016/j.bbrc.2017.06.051",
        "firstpage": "378",
        "issn": "0006291X",
        "keywords": [
            "Chronic myeloid leukemia",
            "LTC-IC",
            "Leukemic stem cells",
            "Leukotriene"
        ],
        "lastpage": "384",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC"
        ],
        "title": "Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in\u00a0vitro growth of CD34+CD38\u2212 stem and progenitor cells in chronic myeloid leukemia"
    }
}